Anacor Pharmaceuticals, Inc.
DelistedCIK 1411158fmd_1NNDNC9MHHE3BCXZZ97RAC16NAManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Mar 31, 2016, 25 periods
| Line item | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | 28 | 20 | 11 | 17 | 21 | 82 |
| Cost of revenue | – | – | – | – | – | 1 | 4 |
| Gross profit | – | – | – | – | – | 20 | 78 |
| Research and development | 34 | 30 | 56 | 52 | 47 | 72 | 74 |
| Selling, general and administrative | – | – | – | 12 | 21 | 31 | 61 |
| Total operating expenses | 41 | 37 | 67 | 64 | (75) | 111 | 139 |
| Operating income | (22) | (9) | (46) | (53) | 93 | (91) | (56) |
| Interest expense | 2 | 2 | 1 | 3 | 4 | 5 | 6 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Other non-operating income (expense) | (0) | 1 | (0) | (0) | (1) | (0) | – |
| Income before taxes | (25) | (10) | (48) | (56) | 86 | (97) | (61) |
| Income tax expense | (0) | – | – | – | 2 | (10) | – |
| Net income from continuing operations | (25) | – | – | – | 85 | (87) | – |
| Net income to common shareholders | (25) | (10) | (48) | (56) | 85 | (87) | (61) |